Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals - Herman, SE M; Gordon, A L; Wagner, A J (Blood, 2010)
et al.